PURPOSE: A single nucleotide polymorphism (SNP) at position 309 in the promoter region of MDM2 leading to increased expression of MDM2 and attenuated function of p53 has been negatively associated with onset and outcome of disease in solid tumors. Because inactivation of p53 by deletion and/or mutations also impacts on the clinical course of B-cell chronic lymphocytic leukemia (B-CLL), we assessed the role of the SNP309 genotype in B-CLL. PATIENTS AND METHODS: The frequency of SNP309 T/T, T/G, or G/G genotypes and the p53 status (wild type, mutated, or deleted) were assessed and correlated with clinical outcome in 140 B-CLL patients and a second independent cohort. In addition, the correlation of the MDM2 SNP309 genotype with the MDM2 protein expression level in B-CLL cells was evaluated by immunoblotting. RESULTS: A significant negative association of the SNP309 T/G and G/G genotypes with overall survival was seen (T/G genotype, relative risk = 3.7; 95% CI, 1.2 to 11.5; P = .02; G/G genotype, relative risk = 9.1; 95% CI, 2.4 to 35.1; P = .001), but no correlation with incidence or onset of B-CLL was observed. The influence of the heterozygous SNP309 T/G genotype on treatment-free survival depended on the p53 status but not on the CD38, Zap-70, or IgVH mutational status or Rai stage of B-CLL patients. The unfavorable SNP309 T/G and G/G genotypes were associated with a gene-dosage-dependent increase of MDM2 expression. CONCLUSION: The MDM2 SNP309 genotype influencing MDM2 expression levels was identified as an additional independent risk factor in B-CLL. Targeting MDM2-p53 interactions might emerge as a successful treatment strategy for B-CLL.
PURPOSE: A single nucleotide polymorphism (SNP) at position 309 in the promoter region of MDM2 leading to increased expression of MDM2 and attenuated function of p53 has been negatively associated with onset and outcome of disease in solid tumors. Because inactivation of p53 by deletion and/or mutations also impacts on the clinical course of B-cell chronic lymphocytic leukemia (B-CLL), we assessed the role of the SNP309 genotype in B-CLL. PATIENTS AND METHODS: The frequency of SNP309 T/T, T/G, or G/G genotypes and the p53 status (wild type, mutated, or deleted) were assessed and correlated with clinical outcome in 140 B-CLL patients and a second independent cohort. In addition, the correlation of the MDM2 SNP309 genotype with the MDM2 protein expression level in B-CLL cells was evaluated by immunoblotting. RESULTS: A significant negative association of the SNP309 T/G and G/G genotypes with overall survival was seen (T/G genotype, relative risk = 3.7; 95% CI, 1.2 to 11.5; P = .02; G/G genotype, relative risk = 9.1; 95% CI, 2.4 to 35.1; P = .001), but no correlation with incidence or onset of B-CLL was observed. The influence of the heterozygous SNP309 T/G genotype on treatment-free survival depended on the p53 status but not on the CD38, Zap-70, or IgVH mutational status or Rai stage of B-CLL patients. The unfavorable SNP309 T/G and G/G genotypes were associated with a gene-dosage-dependent increase of MDM2 expression. CONCLUSION: The MDM2 SNP309 genotype influencing MDM2 expression levels was identified as an additional independent risk factor in B-CLL. Targeting MDM2-p53 interactions might emerge as a successful treatment strategy for B-CLL.
Authors: Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond Journal: Cold Spring Harb Perspect Biol Date: 2009-12-09 Impact factor: 10.005
Authors: Sarah C Roode; Daniel Rotroff; Anne C Avery; Steven E Suter; Dorothee Bienzle; Joshua D Schiffman; Alison Motsinger-Reif; Matthew Breen Journal: Chromosome Res Date: 2015-06-03 Impact factor: 5.239
Authors: Marjanka K Schmidt; Johanna Tommiska; Annegien Broeks; Flora E van Leeuwen; Laura J Van't Veer; Paul D P Pharoah; Douglas F Easton; Mitul Shah; Manjeet Humphreys; Thilo Dörk; Scarlett A Reincke; Rainer Fagerholm; Carl Blomqvist; Heli Nevanlinna Journal: Breast Cancer Res Date: 2009-12-18 Impact factor: 6.466
Authors: Gurinder Singh Atwal; Tomas Kirchhoff; Elisabeth E Bond; Marco Montagna; Marco Monagna; Chiara Menin; Roberta Bertorelle; Maria Chiara Scaini; Frank Bartel; Anja Böhnke; Christina Pempe; Elise Gradhand; Steffen Hauptmann; Kenneth Offit; Arnold J Levine; Gareth L Bond Journal: Proc Natl Acad Sci U S A Date: 2009-06-04 Impact factor: 11.205
Authors: N Faur; L Araud; A Laroche-Clary; J Kanno; J Toutain; T Yamori; J Robert; V Le Morvan Journal: Br J Cancer Date: 2009-06-09 Impact factor: 7.640